Anne Harris
Managing Director
Pfizer Australia and New Zealand
Level 15-18
151 Clarence Street
Sydney 2000



Committee Secretariat
Health Committee
Parliament Buildings
Wellington
Health@parliament.govt.nz

Dear Sir/Madam

Re: Medicines Amendment Bill

Thank you for the invitation to make a submission on the Medicines Amendment Bill (No 2). Pfizer New Zealand is one of the nation's leading providers of prescription medicines. We manufacture medicines and vaccines that thousands of New Zealanders use every day to live longer, healthier and more productive lives.

Pfizer has a proud history in New Zealand. This year marks the company's 61st anniversary of operations here. Throughout this period, we have taken great pride in ensuring patients can access new and innovative medicines and vaccines that are being used to treat and help prevent some of the most feared conditions of our time. We are especially proud to be partnering with the New Zealand Government to deliver a safe and effective COVID-19 vaccine in record time.

Pfizer and BioNTech have put into place a robust COVID-19 vaccine booster research program. In January 2022, we announced a multi-cohort study that looks at a fourth dose of both of the current formulation and Omicron-based variant formulation. The studies for the need of additional boosters are ongoing¹. We will continue to work with regulators around the world as they evaluate a potential framework for future COVID-19 vaccination, booster doses, and vaccine strain selection.

Pfizer intends to submit data from the trial to Medsafe in the coming months. Recommending the use of an additional booster is a decision for the New Zealand Government.

Yours sincerely,

Une days

Anne Harris

Managing Director, Pfizer Australia and New Zealand

¹ <u>To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. - Full Text View - ClinicalTrials.gov</u>